Company news
Zhejiang Hisun Pharmaceutical Co., Ltd. Class A (SSE:600267) news
Zhejiang Hisun Pharmaceutical Co., Ltd. Class A news releases on 6ix. Latest, Dec 18, 2025: Notice on Convening the 1st Extraordinary General Meeting in 2026
Press releases — page 2
Notice on Convening the 1st Extraordinary General Meeting in 2026
December 17, 2025
Announcement on the Wholly-Owned Subsidiary Receiving the CEP Certificate for Everolimus API
December 12, 2025
Announcement on Progress in Public Transfer of 100% Equity in the Wholly-owned Subsidiary Zhejiang Pharmaceutical Industry Corp., Ltd.
December 10, 2025
Announcement on Wholly-owned Subsidiary's Passing GMP Compliance Inspection for Drugs
December 3, 2025
Announcement on Resolutions of the 9th Meeting of the 10th Board of Directors
November 19, 2025
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2025
November 12, 2025
Announcement on Public Transfer of 100% Equity in the Wholly-owned Subsidiary Zhejiang Pharmaceutical Industry Corp., Ltd.
November 11, 2025
Indicative Announcement on Convening the 2nd Extraordinary General Meeting in 2025
November 5, 2025
Announcement on Voluntary Disclosure of Prospective Winning in the National Centralized Drug Procurement
October 29, 2025
Report for Q3 2025
October 27, 2025
Announcement on Convening the Q3 2025 Performance Briefing
October 24, 2025
Announcement on the Revocation of the "GMP Non-Compliance Statement" for the Taizhou Factory by the European Union
October 19, 2025
Announcement on the Company’s Products Obtaining the Self-GRAS Certification from the United States
October 9, 2025
Announcement on Resolutions of the 7th Meeting of the 10th Board of Directors
September 16, 2025
Announcement on the Obtainment of CEP Certificate for Tigecycline Active Pharmaceutical Ingredient
September 12, 2025
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2025
September 10, 2025
Indicative Announcement on Convening the 1st Extraordinary General Meeting in 2025
September 3, 2025
Announcement on Making Provisions for Assets Impairment
August 25, 2025
Announcement on Convening the 2025 Semi-annual Performance Briefing
August 19, 2025
Announcement on Obtaining "Notice of Approval for Marketing Application of Chemical APIs" for Bedaquiline Fumarate API
July 23, 2025
Announcement on Obtaining Notice of Approval for Drug Clinical Trials
July 1, 2025
Announcement on Resolution of the 4th Meeting of the 10th Board of Directors
June 19, 2025
Announcement on Completing Changes in Registered Capital and Business Scope and Obtaining Renewed Business License
June 5, 2025